Gurpreet “Sunny” Singh, Edifecs: Difficult Roads Lead to Wonderful Destinations

July 30th 2021

Gurpreet “Sunny” Singh, chairman of the board at Edifecs, said he follows a philosophy in life that stretches from his time at Montana State University in the 1980s, directly to his work today, at Edifecs, and in India to improve the lives of billions through innovative wellbeing initiatives with RoundGlass. “My father always encouraged me to pursue my passions and to dream big. He also raised me to be generous and compassionate – to honor the human spirit. This is something that I’ve carried with me for my entire life, and it’s shaped the work that I do.”

Closing Gaps in Care: Improving Patient Outcomes and Revenue Recovery

July 29th 2021

Hospitals can't go back to their old ways. They need high-tech, high-touch strategies to engage patients.

An FDA First: Semglee Is Approved As An Interchangeable Biosimilar

July 29th 2021

FDA approval means that pharmacists can swap biosimilar Semglee, an insulin product, for brand-name Lantus, although state-level pharmacy rules may apply.

NextGen Access Decision Makers Influencing Impact on Services and Therapies Across the Healthcare Ecosystem

July 29th 2021

As we come to a stabilizing stage in the pandemic, there is a refocus back to the quest for value-based care. Who will be the next generation access decision makers that will successfully take the triple aim premise of value-based care, couple them with the lessons learned from the pandemic, scale these up, and sustain success over time to make a palpable difference in the U.S. healthcare system?

Vizient’s Outlook Report Is a Mixed Bag: Projected 2022 Drug Spend, White Bagging, Insulin Competition and COVID-19 Treatment. It’s All in There.

July 29th 2021

Wide ranging report covers a lot of ground. It sounds an optimistic note about biosimilars but is critical of white bagging.